T he putative potential of statins to retard the onset and progression of Alzheimer disease (AD) remains controversial. 1, 2 Statin therapy may have the potential to increase nonamyloidogenic soluble amyloid precursor protein ␣ (sAPP␣), thereby reducing ␤-amyloid 42 (A␤ 42 ) and the downstream markers of neurodegeneration phospho-tau (p-tau) and total tau in the cerebrospinal fluid, and thus potentially slow the onset and progression of AD. [3] [4] [5] Thus, in a small but unique cohort of cognitively normal subjects with presenilin 1 (PS1) mutations, we have taken the opportunity to conduct an hypothesis-generating pilot study to assess the effects of intensive statin therapy, using both a lipophilic (simvastatin) and a hydrophilic (atorvastatin) statin. We also studied a second group of subjects without such mutations but with hyperlipidemia (low-density lipoproteins [LDL]Ͼ100 mg/dL) and/or who are heterozygous for apolipoprotein ε4 (APOEε4).
Methods.
Presymptomatic subjects with known PS1 mutations from 2 different kinships (Table) participated in these studies carried out under approval from an institutional review board. After they gave informed consent, subjects meeting the inclusion criteria (PS1 mutation, APOEε4, or APOEε3 with hyperlipidemia [LDLϾ100 mg/dL]) were included. We performed sequential lumbar punctures as well as lipid profiles at baseline and at 6 and 12 months. Cerebrospinal fluid was immediately frozen at −80°C and so maintained prior to testing. Lumbar punctures at each visit were performed for each subject at a standard time of day to eliminate diurnal variability in any analyte. Athena Diagnostics (Worcester, Massachusetts) carried out the Innogenetics methods (Innogenetics, Ghent, Belgium) for determining levels of phospho-tau (hyperphorylated tau, eg, phosphorserine 181), total tau, and A␤ 42 . Concentrations of sAPP␣, and sAPP␤ were measured by enzymelinked immunosorbent assay. 6 All samples were analyzed together to avoid interrun variability. The study design allowed all subjects to act as their own controls. We used an intent-to-treat analysis assessing changes in analytes vs changes in serum lipid levels. Treatment outcomes were evaluated using general linear mixed models to estimate whether there had been a significant change in slope for values of analytes from prestatin levels to those at 6 and 12 months.
Results. All subjects showed profound decreases in both total cholesterol (P Ͻ.001) and LDL (PϽ .001) levels at 6 and 12 months after initiating statin therapy (Table) . In PS1 subjects, statin therapy induced significant de- In the non-PS1 subjects and when controlling for reductions in total cholesterol, sAPP␣ was increased by 9.6% (P=.008) by atorvastatin and 23.7% (PϽ .001) by simvastatin. Increases in sAPP␤ were not significant, but as with the PS1 group, sAPP␣ to sAPP␤ ratios did not change after statin therapy. There were no significant changes in A␤ 42 , p-tau, and total tau.
These results are not easily interpretable based on the assumption that an increase in sAPP␣ occurs with a corresponding decrease in the available APP for cleavage by ␤-secretase. Instead, our results are more consistent with the interpretation that treatment increased either the production or the availability of the APP substrate in non-PS1 subjects and decreased either factor in subjects with PS1 mutations. It remains to be determined whether these differential effects are related to the lipid-lowering or pleiotropic effects of statins.
